64 related articles for article (PubMed ID: 22433252)
1. Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study.
Aoyagi S; Hata H; Homma E; Shimizu H
Oncology; 2012; 82(3):139-46. PubMed ID: 22433252
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis.
Yanagi T; Hata H; Homma E; Kitamura S; Imafuku K; Shimizu H
Clin Exp Dermatol; 2017 Oct; 42(7):781-785. PubMed ID: 28649738
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy and early-stage melanoma.
Daryanani D; Plukker JT; De Hullu JA; Kuiper H; Nap RE; Hoekstra HJ
Cancer; 2003 May; 97(9):2248-53. PubMed ID: 12712479
[TBL] [Abstract][Full Text] [Related]
6. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
8. Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.
Matsumoto T; Yokota K; Sawada M; Sakakibara A; Shibata S; Yasue S; Tomita Y; Yatsuya H; Akiyama M
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1514-20. PubMed ID: 23198869
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
13. [Intralesional therapy of melanoma metastases with recombinant interferon-beta].
Fierlbeck G; d'Hoedt B; Stroebel W; Stutte H; Bogenschütz O; Rassner G
Hautarzt; 1992 Jan; 43(1):16-21. PubMed ID: 1612904
[TBL] [Abstract][Full Text] [Related]
14. Intralesional therapy of metastatic spreading melanoma with beta-interferon.
Rapprich H; Hagedorn M
J Dtsch Dermatol Ges; 2006 Sep; 4(9):743-6. PubMed ID: 16928243
[TBL] [Abstract][Full Text] [Related]
15. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
18. [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].
Bédane C; Le Brun V; Boulinguez S; Berdah JF; Bouyssou ML; Delpuget N; Bernard P; Tubiana-Mathieu N; Bonnetblanc JM
Ann Dermatol Venereol; 1999 Feb; 126(2):142-6. PubMed ID: 10352829
[TBL] [Abstract][Full Text] [Related]
19. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
